Stay updated with breaking news from Hal Barron. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
British drugmaker GlaxoSmithKline on Tuesday snapped up US biopharmaceutical firm Affinivax for up to $3.3 billion, expanding further into vaccines before the demerger of its consumer health care arm
GSK, which is gearing up to separate its consumer unit, has been under pressure to to shore up its vaccine pipeline.
GSK plc (LSE/NYSE: GSK) today announced that it has entered into a definitive agreement to acquire Affinivax, Inc. (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge, Boston, Massachusetts, for a $2.1 billion upfront payment and up to $1.2 billion in potential development milestones ...
LONDON, May 31 — British drugmaker GlaxoSmithKline today snapped up US biopharmaceutical firm Affinivax for up to US$3.3 billion (RM14 billion), expanding further into vaccines...
GSK will pay up to $3.3bn to acquire Affinivax, gaining access to its Multiple Antigen Presenting System (MAPS) technology and vaccine candidates.